Three-Year Outcomes of the Surgery for Trichiasis, Antibiotics to Prevent Recurrence Trial | External Eye Disease | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.108.182. Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
Clinical Trial
Journal Club
Apr 2012

Three-Year Outcomes of the Surgery for Trichiasis, Antibiotics to Prevent Recurrence Trial

Journal Club PowerPoint Slide Download
Author Affiliations

Author Affiliations: Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland (Drs Woreta, Gower, and West and Ms Munoz); and Project ORBIS Ethiopia, Addis Ababa (Dr Alemayehu).

Arch Ophthalmol. 2012;130(4):427-431. doi:10.1001/archophthalmol.2011.374
Abstract

Objective To determine whether treatment with oral azithromycin compared with topical tetracycline reduces the recurrence of trichiasis for up to 3 years following surgery for trichiasis.

Methods The Surgery for Trichiasis, Antibiotics to Prevent Recurrence (STAR) trial is a randomized, single-masked, clinical trial conducted in southern Ethiopia, a region where trachoma is hyperendemic. A total of 1452 patients who underwent trichiasis surgery were randomly assigned at a 2:1 ratio to either a single dose of oral azithromycin (1 g) or topical tetracycline (twice per day for 6 weeks) following surgery.

Main Outcome Measures Recurrence of trichiasis within 3 years following surgery.

Results The rate of recurrence was 10% in the azithromycin group and 13% in the tetracycline group. The azithromycin group had a 22% reduction in recurrence of trichiasis 3 years after surgery compared with the tetracycline group (P = .13). Severity of entropion at baseline was the most significant predictor of recurrence of trichiasis at 3 years.

Conclusion Trichiasis recurrence rates in the STAR trial remained low for up to 3 years following surgery. The protective effect of a single dose of azithromycin was less than at 1 year and, although not statistically significant, was still suggestive up to 3 years following trichiasis surgery.

Application to Clinical Practice A single dose of azithromycin after surgery remains an integral component of the World Health Organization's strategy for the elimination of trachoma by the year 2020.

Trial Registration clinicaltrials.gov Identifier: NCT00347776.

×